Management of hidradenitis suppurativa with biological therapy: Report of four cases and review of the literature

Dermatology

Volumn 229, Issue 4, 2014, Pages 279-287

  Bahillo Monné, Constanza ^a   Honorato Guerra, Silvia ^a   Schoendorff Ortega, Cristina ^a   Gargallo Quintero, Ana Belen ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Acne inversa; Adalimumab; Anti tumor necrosis factor; Etanercept; Hidradenitis suppurativa; Infliximab; Ustekinumab

Indexed keywords

ADALIMUMAB; AMOXICILLIN; ANTIANDROGEN; BOTULINUM TOXIN; CLAVULANIC ACID; CLOXACILLIN; CORTICOSTEROID; CYCLOSPORIN; DOXYCYCLINE; ETANERCEPT; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; PENICILLIN DERIVATIVE; PREDNISONE; RIFAMPICIN; SULFONE; TETRACYCLINE DERIVATIVE;

ADULT; BIOLOGICAL THERAPY; CASE REPORT; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPIDEMIC; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MEDICAL HISTORY; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SKIN DEFECT; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT;

EID: 84917736772     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000365076     Document Type: Review

References (67)

1. Revuz J: Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23:985-998.
2. Danby FW, Margesson LJ: Hidradenitis sup-purativa. Dermatol Clin 2010; 28:779-793.
3. Yazdanyar S, Jemec GB: Hidradenitis suppu-rativa: a review of cause and treatment. Curr Opin Infect Dis 2011; 24:118-123.
4. Alikhan A, Lynch PJ, Eisen DB: Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60:539-561.
5. Jemec GB, Heidenheim M, Nielsen NH: The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Der-matol 1996; 35:191-194.
6. Vinding GR, Miller IM, Zarchi K, Ibler KS, Ellervik C, Jemec GB: The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppura-tiva. Br J Dermatol 2014; 170:884-889.
7. Scheinfeld N: Treatment of coincident seronegative arthritis and hidradenitis suppura-tiva with adalimumab. J Am Acad Dermatol 2006; 55:163-164.
8. Moul DK, Korman NJ: The cutting edge. Severe hidradenitis suppurativa treated with adalim-umab. Arch Dermatol 2006; 142: 1110-1112.
9. Yamauchi PS, Mau N: Hidradenitis suppura-tiva managed with adalimumab. J Drugs Der-matol 2009; 8:181-183.
10. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D: Efficacy of adalimumab in recalcitrant hi-dradenitis suppurativa. Eur J Dermatol 2009; 19:180-181.
11. Harde V, Mrowietz U: Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J Dtsch Dermatol Ges 2009; 7: 139-141.
12. Gorovoy I, Berghoff A, Ferris L: Successful treatment of recalcitrant hidradenitis suppu-rativa with adalimumab. Case Rep Dermatol 2009; 1:71-77.
13. Koilakou S, Karapiperis D, Tzathas C: A case of hidradenitis suppurativa refractory to anti-TNFα therapy in a patient with Crohn's disease. Am J Gastroenterol 2010; 105:231-232.
14. Reddick CL, Singh MN, Chalmers RJ: Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J 2010; 16:15.
15. Alzaga Fernandez AG, Demirci H, Darnley-Fisch DA, Steen DW: Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review. Cornea 2010; 29:1189-1191.
16. Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agu-do M, González-López MA: Long-term successful adalimumab therapy in severe hidrad-enitis suppurativa. Arch Dermatol 2009; 145: 580-584.
17. Arenbergerova M, Gkalpakiotis S, Arenber-ger P: Effective long-term control of refractory hidradenitis suppurativa with adalim-umab after failure of conventional therapy. Int J Dermatol 2010; 49:1445-1449.
18. Amano M, Grant A, Kerdel FA: A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol 2010; 49:950-955.
19. Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E, Ioannides D: A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol 2012; 11:s15-s20.
20. Miller I, Lynggaard CD, Lophaven S, Zacha-riae C, Dufour DN, Jemec GB: A double-blind placebo-controlled randomized trial of adali-mumab in the treatment of hidradenitis sup-purativa. Br J Dermatol 2011; 165:391-398.
21. Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schles-singer J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB: Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157:846-855.
22. Henderson RL Jr: Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept. J Drugs Dermatol 2006; 5: 1010-1011.
23. Zangrilli A, Esposito M, Mio G, Mazzotta A, Chimenti S: Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Der-matol Venereol 2008; 22:1260-1262.
24. Cusack C, Buckley C: Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154:726-729.
25. Giamarellos-Bourboulis EJ, Pelekanou E, An-tonopoulou A, Petropoulou H, Baziaka F, Karagianni V, Stavrianeas N, Giamarellou H: An open-label phase II study of the safety and efficacy of etanercept for the therapy of hi-dradenitis suppurativa. Br J Dermatol 2008; 158:567-572.
26. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, Shin DB, Leyden JJ, Vittorio C, Gelfand JM: A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60:565-573.
27. Sotiriou E, Apalla Z, Ioannidos D: Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol 2009; 89:82-83.
28. López-Martín C, Tortajada Goitia B, Faus Felipe V, Gómez Sánchez A, Ferrer Soler F, Gar-rido Siles M: Respuesta parcial de etanercept en el tratamiento de la hidradenitis supurativa. Farm Hosp 2011; 35:189.e1-189.e4.
29. Adams DR, Yankura JA, Fogelberg AC, Anderson BE: Treatment of hidradenitis suppu-rativa with etanercept injection. Arch Dermatol 2010; 146:501-504.
30. Arriola-Villalobos P, Díaz-Valle D, Alejan-dre-Alba N, López-Abad C, Méndez-Fer-nández R, Benítez-del-Castillo JM: Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa. Eye 2008; 22:599-600.
31. Martínez F, Nos P, Benlloch S, Ponce J: Hi-dradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7:323-326.
32. Katsanos KH, Christodoulou DK, Tsianos EV: Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002; 97: 2155-2156.
33. Roussomoustakaki M, Dimoulios P, Chatzi-costas C, Kritikos HD, Romanos J, Panayio-tides JG, Kouroumalis EA: Hidradenitis sup-purativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003; 38:1000-1004.
34. Lebwohl B, Sapadin AN: Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003; 49(5 suppl):S275-S276.
35. Adams DR, Gordon KB, Devenyi AG, Ioffre-da MD: Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139:1540-1542.
36. Rosi YL, Lowe L, Kang S: Treatment of hi-dradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005; 16:58-61.
37. Thielen AM, Barde C, Saurat JH: Long-term infliximab for severe hidradenitis suppurati-va. Br J Dermatol 2006; 155:1105-1107.
38. Moschella SL: Is there a role for infliximab in the current therapy of hidradenitis suppura-tiva? A report of three treated cases. Int J Der-matol 2007; 46:1287-1291.
39. Benítez-Macías JF, García-Gil D, Brun-Romero FM: Fatal pneumococcal sepsis in patient with hidradenitis suppurative treated with infliximab (in Spanish). Med Clin (Barc) 2008; 131:799.
40. Montes-Romero JA, Callejas-Rubio JL, Sán-chez-Cano D, González-Martínez FJ, Navas-Parejo A, Ortego-Centeno N: Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab. Eur J Intern Med 2008; 19:e32-e33.
41. Elkjaer M, Dinesen L, Benazzato L, Rodriguez J, Løgager V, Munkholm P: Efficacy of inflix-imab treatment in patients with severe fis-tulizing hidradenitis suppurativa. J Crohns Colitis 2008; 2:241-245.
42. Antonucci A, Negosanti M, Negosanti L, Ioz-zo I, Varotti C: Acne inversa treated with in-fliximab: different outcomes in 2 patients. Acta Derm Venereol 2008; 88:274-275.
43. Poulin Y: Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg 2009; 13:221-225.
44. Goertz RS, Konturek PC, Naegel A, Janka R, Amann K, Maennlein G, Wein A, Hahn EG, Boxberger F: Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit 2009; 15:CS14-CS18.
45. Yazdanyar S, Miller IM, Jemec GB: Hidrade-nitis suppurativa and Crohn's disease: two cases that support an association. Acta Der-matovenerol Alp Pannonica Adriat 2010; 19: 23-25.
46. García-Rabasco AE, Esteve-Martínez A, Za-ragoza-Ninet V, Sánchez-Carazo JL, Alegre-de-Miquel V: Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature. Actas Der-mosifiliogr 2010; 101:717-721.
47. Lasocki A, Sinclair R, Foley P, Saunders H: Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol 2010; 51:186-190.
48. Alecsandru D, Padilla B, Izquierdo JA, Fer-nández-Cruz E, Sánchez-Ramón S: Severe refractory hidradenitis suppurativa in an HIVpositive patient successfully treated with infliximab. Arch Dermatol 2010; 146:1343-1345.
49. Torres T, Selores M: Treatment of hidradeni-tis suppurativa with infliximab. An Bras Der-matol 2010; 85:576.
50. De Souza A, Solomon GE, Strober BE: SA-PHO syndrome associated with hidradenitis suppurativa successfully treated with inflix-imab and methotrexate. Bull NYU Hosp Jt Dis 2011; 69:185-187.
51. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS: Infliximab for hidradenitis sup-purativa. Br J Dermatol 2003; 149:1046-1049.
52. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, Bachelez H, Morel P, Lebbé C: In-fliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56:624-628.
53. Usmani N, Clayton TH, Everett S, Goodfield MD: Variable response of hidradenitis sup-purativa to infliximab in four patients. Clin Exp Dermatol 2007; 32:204-205.
54. Fernández-Vozmediano JM, Armario-Hita JC: Infliximab for the treatment of hidradeni-tis suppurativa. Dermatology 2007; 215:41-44.
55. Pedraz J, Daudén E, Pérez-Gala S, Goiriz-Val-dés R, Fernández-Peñas P, García-Díez A: Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr 2007; 98:325-331.
56. Brunasso AM, Delfino C, Massone C: Hidrad-enitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol 2008; 159:761-763.
57. Delage M, Samimi M, Atlan M, Machet L, Lo-rette G, Maruani A: Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol 2011; 91:169-171.
58. Van Rappard DC, Mekkes JR: Treatment of severe hidradenitis suppurativa with inflix-imab in combination with surgical interventions. Br J Dermatol 2012; 167:206-208.
59. Mekkes JR, Bos JD: Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158:370-374.
60. Paradela S, Rodríguez-Lojo R, Fernández-Torres R, Arévalo P, Fonseca E: Long-term efficacy of infliximab in hidradenitis suppura-tiva. J Dermatolog Treat 2012; 23:278-283.
61. Grant A, González T, Montgomery MO, Cardenas V, Kerdel FA: Infliximab therapy for patients with moderate to severe hidradeni-tis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62:205-217.
62. Van Rappard DC, Mooij JE, Baeten DL, Mek-kes JR: New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab. Br J Dermatol 2011; 165:194-198.
63. Lozeron P, Denier C, Lacroix C, Adams D: Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66: 490-497.
64. Van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR: Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppura-tiva. J Dermatolog Treat 2012; 23:284-289.
65. Brunasso AM, Massone C: Rotational therapy with TNF-alpha blockers for recalcitrant hi-dradenitis suppurativa. Eur J Dermatol 2010; 20:644-646.
66. Gulliver WP, Jemec GB, Baker KA: Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26: 911-914.
67. Sharon VR, Garcia MS, Bagheri S, Goodarzi H, Yang C, Ono Y, Maverakis E: Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 92: 320-321.